ReviewJournal of ophthalmic & vision research2026
Quality of Life in Patients with Posterior Segment Eye Diseases.
Review in Journal of ophthalmic & vision research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior segment eye diseases pose a significant threat to vision-related quality of life, affecting functional independence, psychological health, and social well-being. Conditions such as diabetic retinopathy and age-related macular degeneration are leading causes of blindness, often resulting in severe emotional distress and reduced mobility. Optic neuritis and optic neuropathy can lead to vision loss and increase the risk of depression, particularly in patients with multiple sclerosis. Retinal disorders like central serous chorioretinopathy and retinitis pigmentosa disrupt daily tasks such as reading and driving, thus leading to social isolation and economic burden. Hypertensive retinopathy and retinal detachment further contribute to vision impairment, with long-term implications for functional ability and mental health. Inherited retinal diseases such as Stargardt disease and Leber congenital amaurosis significantly reduce quality of life from an early age and negatively affect education, employment opportunities, and psychological well-being. Additionally, the economic impact of these diseases is substantial, with high treatment costs and productivity loss. On the other hand, vision rehabilitation, psychological support, and advancements in gene and pharmacological therapy can largely mitigate the adverse effects on quality of life associated with posterior segment diseases. Therefore, a comprehensive approach that integrates medical, psychological, and social interventions is essential for improving patient outcomes. Future research should focus on developing innovative treatments and patient-centered care strategies to improve the quality of life for individuals affected by this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.